A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

Summary

This trial is a phase 1, randomized, double-blind, placebo-controlled trial conducted in Chinese Healthy Volunteers and Patients with moderate-to-severe Atopic Dermatitis It aims to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of single and multiple doses of SM17 injection in healthy subjects . It also aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect and immunogenicity as well as preliminary efficacy in AD patients.

Timeline

Start

2023-11-21

Primary completion

2025-03-24

Completion

2025-03-31

Outcome

Met primary endpoint

release “This Phase1b study, which evaluated two doses level of SM17 (200mg and 600mg, respectively), met its primary endpoints manifested as the safety profiles” sinomab.com ↗

Drugs

Indications